Human eukaryotic release factor 3a depletion causes cell cycle arrest at G1 phase through inhibition of the mTOR pathway

被引:38
作者
Chauvin, Celine [1 ]
Salhi, Samia [1 ]
Jean-Jean, Olivier [1 ]
机构
[1] Univ Paris 06, CNRS, UMR 7098, Unite Biochim Cellulaire, F-75252 Paris 05, France
关键词
D O I
10.1128/MCB.00035-07
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Eukaryotic release factor 3 (eRF3) is a GTPase associated with eRF1 in a complex that mediates translation termination in eukaryotes. Studies have related eRF3 with cell cycle regulation, cytoskeleton organization, and tumorigenesis. In mammals, two genes encode two distinct forms of eRF3, eRF3a and eRF3b, which differ in their N-terminal domains. eRF3a is the major factor acting in translation termination, and its expression level controls termination complex formation. Here, we investigate the role of eRF3a in cell cycle progression using short interfering RNAs and flow cytometry. We show that eRF3a depletion induces a G, arrest and that eRF3a GTP-binding activity, but not the eRF3a N-terminal domain, is required to restore G(1)-to-S-phase progression. We also show that eRF3a depletion decreases the global translation rate and reduces the polysome charge of mRNA. Finally, we show that two substrates of the mammalian TOR (mTOR) kinase, 4E-BP1 and protein kinase S6K1, are hypophosphorylated in eRF3a-depleted cells. These results strongly suggest that the G, arrest and the decrease in translation induced by eRF3a depletion are due to the inhibition of mTOR activity and hence that eRF3a belongs to the regulatory pathway of mTOR activity.
引用
收藏
页码:5619 / 5629
页数:11
相关论文
共 48 条
  • [1] Barbe Esther, 1996, MEDITERR POLIT, V1, P25
  • [2] Basu J, 1998, CELL MOTIL CYTOSKEL, V39, P286, DOI 10.1002/(SICI)1097-0169(1998)39:4<286::AID-CM4>3.0.CO
  • [3] 2-1
  • [4] Recessive mutations in SUP35 and SUP45 genes coding for translation release factors affect chromosome stability in Saccharomyces cerevisiae
    Borchsenius, AS
    Tchourikova, AA
    Inge-Vechtomov, SG
    [J]. CURRENT GENETICS, 2000, 37 (05) : 285 - 291
  • [5] Polyglycine expansions in eRF3/GSPT1 are associated with gastric cancer susceptibility
    Brito, M
    Malta-Vacas, J
    Carmona, B
    Aires, C
    Costa, P
    Martins, AP
    Ramos, S
    Conde, AR
    Monteiro, C
    [J]. CARCINOGENESIS, 2005, 26 (12) : 2046 - 2049
  • [6] Stop codon suppression via inhibition of eRF1 expression
    Carnes, J
    Jacobson, M
    Leinwand, L
    Yarus, M
    [J]. RNA, 2003, 9 (06) : 648 - 653
  • [7] Involvement of human release factors eRF3a and eRF3b in translation termination and regulation of the termination complex formation
    Chauvin, C
    Salhi, S
    Le Goff, C
    Viranaicken, W
    Diop, D
    Jean-Jean, O
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 2005, 25 (14) : 5801 - 5811
  • [8] The polypeptide chain release factor eRF1 specifically contacts the s4UGA stop codon located in the A site of eukaryotic ribosomes
    Chavatte, L
    Frolova, L
    Kisselev, L
    Favre, A
    [J]. EUROPEAN JOURNAL OF BIOCHEMISTRY, 2001, 268 (10): : 2896 - 2904
  • [9] Upstream of the mammalian target of rapamycin: do all roads pass through mTOR?
    Corradetti, M. N.
    Guan, K-L
    [J]. ONCOGENE, 2006, 25 (48) : 6347 - 6360
  • [10] Poly(A)-binding protein and eRF3 are associated in vivo in human and Xenopus cells
    Cosson, B
    Berkova, N
    Couturier, A
    Chabelskaya, S
    Philippe, M
    Zhouravleva, G
    [J]. BIOLOGY OF THE CELL, 2002, 94 (4-5) : 205 - 216